Stock Evaluator: Latigo Biotherapeutics, Inc. (LTGO)
Latigo Biotherapeutics, Inc. LTGO
$22.10
0.56
2.58%
September 11, 2026 3:31:14 PM
EST
Volume: 141,202
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Financial Summary
| Share Statistics | LTGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,428.1 | $626.3 | 50% |
|
| Shares Out (Mil) | 0.9 | 43.4 | 4% |
|
| Institutional Ownership | 42.1% | 83.9% | 18% |
|
| Float (Mil) | 18.7 | 45.7 | 28% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 221 | 309 | 47% |
|
| Price Change (52-week) |
na | 66.6% | na |
|
| Growth | LTGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LTGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($111) | ($11) | 10% |
|
| EPS (TTM) | ($116.740) | ($0.700) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($103) | ($6) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 15% |
|
| Enterprise Value (Q1) (Mil) | $1,838 | $525 | 48% |
|
| Valuation | LTGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.69 | na |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LTGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (343.2%) | (24.1%) | 1% |
|
| ROE | 80.5% | (21.4%) | 95% |
|
| Liabilities to Assets | 80.7% | 33.1% | 75% |
|
| F-Score | 1 | 3 | na |
|
Latigo Biotherapeutics, Inc. did not pass any screens on 9/10/2026.
